Global Chemotherapy-Induced Alopecia Treatment Market By Product (Automated Scalp Cooling Systems, Manual Cold Cap Systems), By End User (Hospitals, Cancer Therapy Centers, Home Care Settings), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

Alopecia, commonly known as baldness or hair loss, is the loss of hair on one’s head or body. The disease can affect both men and women, and it can strike at any age. Androgenic alopecia, alopecia areata, alopecia totalis, cicatricial alopecia, and telogen effluvium are the five major types of alopecia.

Alopecia areata is an autoimmune condition that targets the hair follicles, resulting in hair loss or breakage, and eventually complete baldness. Hormonal changes, inherited conditions, radiation therapy, stress, and the use of certain drugs and supplements are among the causes of male-pattern alopecia and female-pattern alopecia.

Alopecia therapy is important in advanced healthcare since it aids in the prevention of hair loss and hair restoration. Drugs such as minoxidil, finasteride, 5-alpha-reductase inhibitors, corticosteroids, and cyclosporine can be used to treat hair loss. Hair transplantation, scalp reduction, and laser therapy are among the surgical therapies for alopecia.

The growing number of cancer cases is subsequently increasing the demand for chemotherapy drug administration. Chemotherapy causes several side effects among which alopecia is one of the most common side effects. Chemotherapy-induced alopecia is a common problem associated with a different kind of chemotherapy. The need for chemotherapy drugs increases as the number of cancer cases continues to surge.

Chemotherapy has a wide range of adverse effects, including alopecia, which is one of the most prevalent. Chemotherapy-induced alopecia is a typical side effect of a specific type of chemotherapy. The use of scalp cooling to treat chemotherapy-induced alopecia is becoming more prevalent. Scalp cooling is based on the notion of temperature decrease. Reduced blood supply to the scalp results in less hair loss when the temperature is lowered.

Detailed Segmentation –

Based on Product Type:

• Automated Scalp Cooling Systems
• Manual Cold Cap Systems

Based on End User:

• Hospitals
• Cancer Therapy Centers
• Home Care Settings

Based on Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics –

Drivers for the Global Chemotherapy-Induced Alopecia Treatment Market:

As the prevalence of cancer Increases, so will the demand for chemotherapy-induced alopecia treatments, as the number of people seeking treatment and using chemotherapy continues to surge. The chemotherapy-induced alopecia treatment market is expected to augment due to increasing treatment affordability and awareness.

Restraints Global Chemotherapy-Induced Alopecia Treatment Market:

Adverse effects related to scalp cooling, including headaches, scalp pain, and chills are restraining the economic growth of the chemotherapy-induced alopecia treatment market.

Opportunities for the Global Chemotherapy-Induced Alopecia Treatment Market:

The market for chemotherapy-induced alopecia treatments is anticipated to expand due to an increase in genetic disorders and hereditary cancer. The expansion of the chemotherapy-induced alopecia treatment market is projected to be aided by increased new product development activities and FDA approvals.

Trends for the Global Chemotherapy-Induced Alopecia Treatment Market:

Hair to Stay, Cold Capital Fund, and Hope for Hair are among the initiatives intended to boost the demand for chemotherapy-induced alopecia treatment products. Manufacturers are working to create a viable treatment option for chemotherapy-induced alopecia. Based on a patient’s age and chemotherapy protocol, manufacturers design a sensor-controlled scalp cooling system.

Competitive Landscape –

• Dignitana AB
• Paxman
• Penguin Cold Caps
• Arctic Cold Caps LLC.
• Wishcaps
• Warrior Caps

Recent Developments of Major Players –

• In December, 2015, the DigniCap system was authorized by the FDA for the treatment of chemotherapy-induced alopecia.
• The FDA approved the Paxman scalp cooling system in April, 2017.

For the Chemotherapy-Induced Alopecia Treatment Market research study, the following years have been considered to estimate the market size: